Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database

OBJECTIVE: To report long-term safety from the completed extension trial of baricitinib, an oral selective Janus kinase inhibitor, in patients with active rheumatoid arthritis (RA). METHODS: Treatment-emergent adverse events are summarised from an integrated database (9 phase III/II/Ib and 1 long-te...

Descripción completa

Detalles Bibliográficos
Autores principales: Taylor, Peter C, Takeuchi, Tsutomu, Burmester, Gerd R, Durez, Patrick, Smolen, Josef S, Deberdt, Walter, Issa, Maher, Terres, Jorge Ross, Bello, Natalia, Winthrop, Kevin L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8862028/
https://www.ncbi.nlm.nih.gov/pubmed/34706874
http://dx.doi.org/10.1136/annrheumdis-2021-221276

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8862028/
https://www.ncbi.nlm.nih.gov/pubmed/34706874
http://dx.doi.org/10.1136/annrheumdis-2021-221276

Ejemplares similares